AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05026671 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Tube Alone
Description: Intubating the trachea with an endotracheal tube alone ( without stylet).
Study NCT04695873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corn Foam Cushion
Description: An anatomically shaped foam pad with a central hole. The upper layer is made from a honeycomb of interconnecting cells, the external facing surface is smooth, the underside is coated with adhesive.
Study NCT04488458 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MIC or MBEC+MIC based treatment algorithm
Description: i) Non cell wall active standard of care antibiotic combination (MIC-guided) for 6 weeks.~ii) Non cell wall active antibiotic combination according to a MBEC-based decision algorithm for 6 weeks.
Study NCT04488458 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MIC or MBEC+MIC based treatment algorithm
Description: i) Non cell wall active standard of care antibiotic combination (MIC-guided) for 6 weeks.~ii) Non cell wall active antibiotic combination according to a MBEC-based decision algorithm for 6 weeks.
Study NCT06042673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate seed oil
Description: 10 g of pomegranate seed oil+40g mixed oil (palm oil/ rapeseed oil/ safflower oil (4:0.5:0.5)) will be added to the test meal for breakfast
Study NCT06042673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mixed vegetable oil
Description: 50g mixed oil (palm oil/ rapeseed oil/ safflower oil (4:0.5:0.5)) will be added to the test meal for breakfast
Study NCT05026671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endotracheal Tube+ Stylet
Description: Intubating the trachea with an endotracheal tube + stylet.
Study NCT05026671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endotracheal Tube + Video-laryngoscope
Description: Intubating the trachea with an endotracheal tube + Video- laryngoscope
Study NCT05026671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endotracheal tube + stylet with Video-laryngoscope
Description: Intubating the trachea with an endotracheal tube + stylet + Video-laryngoscope
Study NCT05050448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sustained Acoustic Device with 2.5% Diclofenac Patch
Description: Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm@ with 2.5% Diclofenac patches.
Study NCT05050448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1% Diclofenac Topical Gel
Description: Topical pain-relief gel
Study NCT04448106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Celltex- AdMSCs
Description: Autologous adipose-derived stem cells Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
Study NCT04448106 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Celltex- AdMSCs
Description: Autologous adipose-derived stem cells Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
Study NCT06370507 — intervention group
Intervention type: DEVICE
Intervention: Electrical impedance tomography assessment of ventilation distribution in course of sedation/general anesthesia for pediatric surgery
Description: Assessment of ventilation distribution through electrical impedance tomography in pediatric patients subjected to sedation or general anesthesia for surgery
Study NCT04865952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal surgery + 24 hr buccal attached gingiva (G) biopsy
Description: Periodontal surgery will be performed and 24 hr after the surgical procedure a 2mm punch biopsy will be harvested at the level of the buccal attache gingiva (G).
Study NCT04865952 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: periodontal surgery + 24 hr buccal attached gingiva (G) biopsy
Description: Periodontal surgery will be performed and 24 hr after the surgical procedure a 2mm punch biopsy will be harvested at the level of the buccal attache gingiva (G).
Study NCT04865952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HA application
Description: HA will be applied at the end of the surgical procedure, at the level of the vertical released incisions (VRIs) and over VRIs
Study NCT05481840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continence material with sensor
Description: Healthcare organizations are prepared for the use of smart continence care (for the intervention condition) using specially developed implementation guideline. They receive training, including how to apply continence material (only provided to intervention condition).~Each participating location will use the product for 12 weeks. Correct size and absorption level will be determined for each participant. The optimize the result, this can change. Evaluation meetings with the caregivers, supplier and researcher will be held. Resulting in suggestions for alterations in continence care provided or products used, or giving indications that a team needs support in any way to foster the implementation.~After 12 weeks, the implementation guidance from the research group will be phased out.~The waiting list group will continue their continence care as usual during data collection period. Thereafter they will receive support for implementing smart continence care.
Study NCT05638971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ivWatch
Description: The second half sample size PIVC will be enrolled into an alarming group. ivWatch will monitor the PIVC insertion site collecting data and sending visual and auditory notifications of any infiltration. The goals of the study on the alarming group are: a) to estimate the notification rate (the number of detected infiltration in the studied period; b) to evaluate the extension and severity of the detected infiltration at the time of the notification, so to gather if ivWatch is helpful in early diagnosis
Study NCT04408144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone 10mg Oral Tablet
Description: oral 10mg dydrogesterone (Duphaston) 2 times daily
Study NCT05315739 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive transcutaneous vagus nerve stimulation (tVNS)
Description: tVNS delivers an electrical current to the cervical branch of the vagus nerve. Four minutes of bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2) are performed. The two periods are separated by a 2 weeks wash-out period.
Study NCT05315739 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vagus nerve stimulation
Description: The sham device produces a slight vibrating sound, but does not produce an electical current and hence, does not activate the vagus nerve.~Four minutes of bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period.
Study NCT06381193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: oral, daily
Study NCT06381193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: oral, daily
Study NCT05033834 — intervention group
Intervention type: OTHER
Intervention: covid-19 vaccines registered in Egypt
Description: Astra Zeneka vaccine, Sinopharm vaccine, Sinovac vaccine, Jonson and Jonson vaccine, Spotnic V vaccine
Study NCT05098886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5210 10/1000mg
Description: single dose administration (one tablet once a day)
Study NCT05098886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5210-R 10/1000mg
Description: single dose administration (one tablet once a day)
Study NCT05016063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
Study NCT05016063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
Study NCT05016063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dual CD33-CLL1 CAR-T cells
Description: CD33-CLL1 CAR-T infusion (starting at dose level 1 \[DL1\]: 0.5 x 106 transduced CAR-T cells/kg) on Day 0.
Study NCT06381193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic + Prebiotic
Description: oral, daily
Study NCT06381193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, daily
Study NCT05518890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Only
Description: Participants caloric intake will be reduced by 5000kcal per week over 4 weeks
Study NCT06251011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 1. Physical therapy training via video call~2. An advise and a leaflet for cardiopulmonary rehabilitation
Study NCT05443139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Well-being online
Description: Multi component Intervention composed 10 sessions following a structure based on Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), Positive Psychology (PP), Mindfulness and Behavioral Activation Therapy (BAT).
Study NCT00678678 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incentive Spirometry - RESPIRON
Description: Device that stimulates the deep breathing, flow-oriented
Study NCT00678678 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kit Epap®:
Description: Device that providing constant positive pressure during expiration, given by spring load (cmH2O), using a face mask as an interface
Study NCT05934669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Midazolam
Description: Using a computer-generated randomization schedule by the research pharmacist, all 90 subjects will be divided into 3 even groups to receive either medication A (intranasal Midazolam), B (intranasal Dexmedetomidine), or C (intranasal Ketamine). Based on the randomization schedule, the pharmacist will dispense medication A, B, or C to the chronological number provided in the order. The total amount of the medication will be based on the patient's charted weight. Small volumes of less than 1ml per nostril are preferred for reliable absorption; therefore, the medication will be dispensed in a 1ml syringe and the barrel of the syringe will be covered by the pharmacist. All the syringes sent from the pharmacy will appear the same, regardless of the volume of the medication.
Study NCT05934669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine
Description: See above
Study NCT05934669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Ketamine
Description: See above
Study NCT05699473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-MTHF glucosamine salt
Description: Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) glucosamine salt
Study NCT05699473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-MTHF calcium salt 1
Description: Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) calcium salt, crystal form 1
Study NCT05699473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-MTHF calcium salt 2
Description: Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) calcium salt, crystal form 2
Study NCT05518890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet plus Exercise
Description: Participants caloric intake will be reduced by 5000kcal per week over 4 weeks. Participants will also be asked to perform 5x30 minute cycling exercise sessions at home. Each week the intensity of exercise will be increased (week 1 = RPE 12, week 2 = RPE 13, week 3 = RPE 14, week 4 = RPE 15)
Study NCT04711980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mudan granule
Description: Mudan granule,a traditional Chinese medicine formula,consists of nine Chinese herbs.~Other: Standard medical care.Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
Study NCT04711980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Granule(Placebo) is in accordance with Mudan granule in appearance, colour, taste.~Other: Standard medical care. Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
Study NCT04775745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-168
Description: For the dose escalation phase, LP-168 will be given once or twice daily at the following dose levels:100 mg QD,150 mg QD, 100 mg BID, 300 mg QD, 150 mg BID, 450 mg QD, 225 mg BID, 600 mg QD, 800 mg QD, and 1000 mg QD.
Study NCT04775745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-168
Description: For the dose expansion phase, subjects will receive once or twice daily dose of LP-168 at the Recommended Phase 2 Dose (RP2D). The RP2D may be as high as the MTD and will be determined following evaluation of Phase I Dose Escalation results.
Study NCT04763746 — intervention group
Intervention type: DEVICE
Intervention: Lifelight Data Collect Sub-protocol 1
Description: Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will observe the oxygen saturation measurements during this 60-second measurement period, noting down the first reading displayed at 0, 30 and 60 seconds. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading.~Study nurse 2 will operate the automatic sphygmomanometer upon hearing from study nurse 1 that the 60-second measurement period has begun. Study nurse 2 will then spend the remaining measurement period observing the heart rate measurements and note the reading displayed after 0, 30 and 60 seconds. The three heart rate readings should be averaged to generate a single, average heart rate reading.~This sub-protocol will be repeated twice more to generate three sets of blood pressure, heart rate and oxygen saturation measurements and three concurrent video datasets.
Study NCT04763746 — intervention group
Intervention type: DEVICE
Intervention: Lifelight Data Collect Sub-protocol 2
Description: Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will observe the oxygen saturation measurements during this 60-second measurement period noting down the first reading displayed at 0, 30 and 60 seconds timepoints. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading.~Study nurse 2 will be directed by the announcement of study nurse 1 to begin and end manually counting observed inspirations by watching chest rises throughout the full 60-second period. According to the results of the quality improvement initiative, Study nurse 2 may place their hand on the participant's chest to increase the accuracy of their manual counting.~This sub-protocol will be repeated once more to generate two sets of respiratory rate and oxygen saturation measurements and two concurrent video datasets.
Study NCT04763746 — intervention group
Intervention type: DEVICE
Intervention: Lifelight Data Collect Sub-protocol 3
Description: The study nurse will observe the oxygen saturation measurements during this 60-second measurement period indicated by the timer on the software. They will note down the first reading displayed after 0, 30 and 60 seconds. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading for the 60-second period.~This sub-protocol will be repeated once more to generate two sets of oxygen saturation measurements and two concurrent video datasets.
Study NCT04763746 — intervention group
Intervention type: DEVICE
Intervention: Lifelight Data Collect Sub-protocol 4
Description: Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will manually count observed inspirations by watching chest rises throughout the 60-second period. They may place their hand on the participant's chest to increase the accuracy of manual counting.~Study nurse 2 will operate a standard automatic sphygmomanometer and clinical finger clip sensor upon hearing from Study nurse 1 that the 60-second measurement period has begun. Study nurse 2 will then spend the remaining measurement period observing these measurements and note the readings displayed after 0, 30 and 60 seconds. The three heart rate and three oxygen saturation readings will each be averaged to generate a single, average reading.~This sub-protocol will be repeated twice more to generate three sets of blood pressure, heart rate, respiratory and oxygen saturation measurements and three concurrent video datasets.
Study NCT04700774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation
Description: Brief Behavioral Activation Treatment with and without motor enhancement. All patients will receive 10 online video sessions. BA focuses on increasing overt behaviors to bring patients into contact with reinforcing environmental contingencies and corresponding improvements in thoughts, mood, and quality of life (Hopko, Lejuez, et al., 2003). BA follows the basic behavioral principles of extinction, shaping, fading, and in vivo exposure (Hopko \& Lejuez, 2007; Lejuez et al., 2001, 2011). In the mBA condition only a) patients will be introduced to the idea that the motor system can be used in the service of action initiation and will receive an audio recording with motor manipulations to assist in action initiation and b) the therapist will conduct imaginary behavioral activation and - in session - complete questionnaires identical to those in the experiment before and after the bodily instructions presented in the treatment.
Study NCT05824143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darigabat
Description: Oral tablet
Study NCT05824143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Oral tablets
Study NCT05860647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation
Description: MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz
Study NCT06548321 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy
Description:  The ESTW machine is turned on and the instrument, or shockwave gun, is pressed against the affected area. Rapid impulses are then delivered to the patient. Treatment typically lasts between 5 and 15 minutes. While this treatment can be uncomfortable for some, most do not experience any pain.~Once treatment is completed, patients should do their best to physical activity... higher levels of energy Shockwaves into deeper tissue locations... ESWT therapies can help treat neurological disorders like multiple sclerosis and the effects of stroke.
Study NCT05750992 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical TAP block
Description: performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally by the surgeon.
Study NCT05750992 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US guided TAP block
Description: performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally.
Study NCT05288582 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NovaTears
Description: Over-the-counter eye drop
Study NCT04397484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% Levobupivacaine
Description: The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
Study NCT04397484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Xylocaine with adrenaline 1:200,000
Description: The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
Study NCT06405971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients in the drug group took one tablet of metformin hydrochloride enteric capsule orally each day after breakfast and dinner, and the dose of each tablet was 250mg.
Study NCT06405971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Patients in the drug group took one tablet of metformin hydrochloride enteric capsule orally each day after breakfast and dinner, and the dose of each tablet was 250mg.